Barber and colleagues conducted another investigation to further elaborate on the applicability of T cells engineered with NKG2D-based chimeric receptors (designed in the previous study) by determining if adoptive transfer of these T cells could prolong the survival of ovarian cancer animal models, and whether the immune system of the treatment subjects could mount responses to antigens associated with ovarian cancer (123). Here, KLRK1 is linked to ovarian carcinoma.